ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

Phase 1

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar pegol

First Posted Date: 2017-11-08

Last Posted Date: 2018-11-01

Lead Sponsor: Allergan

Target Recruit Count: 11

Registration Number: NCT03335852

Locations: 🇯🇵
Takeuchi Eye Clinic, Taito-ku, Tokyo, Japan
🇯🇵
Kimura Eye and Internal Medicine Hospital, Kure, Hiroshima, Japan
🇯🇵
Musashi Dream Clinic, Tennouji-ku, Osaka, Japan

and more 2 locations

Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control

Not Applicable

Completed

Conditions: Dry Eye Syndromes

Interventions: Device: TrueTear Sham Control
Device: TrueTear

First Posted Date: 2017-10-30

Last Posted Date: 2019-12-18

Lead Sponsor: Allergan

Target Recruit Count: 84

Registration Number: NCT03325673

Locations: 🇨🇦
Centre for Contact Lens Research School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada

BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

Phase 2

Completed

Conditions: Urinary Incontinence
Overactive Bladder With Urinary Incontinence

Interventions: Drug: OnabotulinumtoxinA and Hydrogel admixture
Drug: Placebo and Hydrogel admixture

First Posted Date: 2017-10-25

Last Posted Date: 2021-08-13

Lead Sponsor: Allergan

Target Recruit Count: 383

Registration Number: NCT03320850

Locations: 🇺🇸
Urological Assoc. of South AZ, Tucson, Arizona, United States
🇺🇸
Adult and Pediatric Urology, Bridgeport, Connecticut, United States
🇺🇸
CT Clinical Research Center/Urologist Specialist, Middlebury, Connecticut, United States

and more 60 locations

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

Phase 1

Withdrawn

Conditions: Alzheimer's Disease

Interventions: Drug: AGN-242071
Drug: Placebo
Drug: Donepezil
Drug: Memantine

First Posted Date: 2017-10-20

Last Posted Date: 2018-11-02

Lead Sponsor: Allergan

Registration Number: NCT03316898

Locations: 🇺🇸
Synergy Research Centers, Lemon Grove, California, United States
🇺🇸
Collaborative Neuroscience, Long Beach, California, United States
🇺🇸
Alliance Research, Long Beach, California, United States

and more 3 locations

Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Retinol Complex 0.5
Other: Facial cleanser
Other: Moisturizing lotion
Other: Sunscreen
Device: Skin Imaging

First Posted Date: 2017-10-05

Last Posted Date: 2019-06-04

Lead Sponsor: Allergan

Target Recruit Count: 29

Registration Number: NCT03302559

Locations: 🇺🇸
SkinMedica Clinical Research and Innovation Center, Irvine, California, United States

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Phase 3

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Relamorelin

First Posted Date: 2017-09-18

Last Posted Date: 2021-07-29

Lead Sponsor: Allergan

Target Recruit Count: 336

Registration Number: NCT03285308

Locations: 🇺🇸
Digestive Health Specialist of the South East, Dothan, Alabama, United States
🇺🇸
Aurora Care Clinic, LLC, Costa Mesa, California, United States
🇺🇸
Savin Medical Group LLC, Miami Lakes, Florida, United States

and more 202 locations

Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use

Not Applicable

Terminated

Conditions: Dry Eye Syndromes

Interventions: Device: TrueTear™ Application

First Posted Date: 2017-09-07

Last Posted Date: 2021-03-08

Lead Sponsor: Allergan

Target Recruit Count: 10

Registration Number: NCT03274999

Locations: 🇬🇧
Ocular Technology Group International, London, United Kingdom

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Phase 4

Completed

Conditions: Acute Bacterial Skin and Skin Structure Infection
Bacterial Infections

Interventions: Drug: Usual Care
Drug: Dalbavancin

First Posted Date: 2017-07-28

Last Posted Date: 2020-01-18

Lead Sponsor: Allergan

Target Recruit Count: 91

Registration Number: NCT03233438

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

Not Applicable

Completed

Conditions: Dry Eye Syndromes
Meibomian Glands

Interventions: Device: Thermalon Dry Eye Compress
Device: TrueTear™

First Posted Date: 2017-07-24

Last Posted Date: 2020-10-30

Lead Sponsor: Allergan

Target Recruit Count: 57

Registration Number: NCT03226769

Locations: 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States

Optive Brand For Day And Night Dry Eye Management

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Device: Optive® Fusion + Optive® Gel Drop

First Posted Date: 2017-07-05

Last Posted Date: 2019-06-20

Lead Sponsor: Allergan

Target Recruit Count: 35

Registration Number: NCT03208673

Locations: 🇬🇧
Ocular Technology Group - international, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy